Drug intelligence / Profile preview

REV101

Development stage: Unknown
Lead developer: Revive Therapeutics
Modality: Small Molecules

Overview

REV101 is a discontinued investigational drug that was initially developed by Revive Therapeutics. It was explored for use in immune-related therapeutic areas, but development has been halted and the drug is no longer in active clinical development. No detailed information about its mechanism of action, molecular target, or specific indications beyond the general immune area has been published in accessible sources[1].

Targets

NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)

Beyond the preview

Go deeper on REV101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REV101.

Explore the full profile